85 related articles for article (PubMed ID: 2558540)
1. The relationship between dihydroorotic acid dehydrogenase and in vitro and in vivo cytostatic effects of brequinar sodium (DUP-785; NSC 368390).
Peters GJ; Laurensse E; de Kant E; Nadal JC; Pinedo HM
Adv Exp Med Biol; 1989; 253B():375-82. PubMed ID: 2558540
[No Abstract] [Full Text] [Related]
2. Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer.
Peters GJ; Nadal JC; Laurensse EJ; de Kant E; Pinedo HM
Biochem Pharmacol; 1990 Jan; 39(1):135-44. PubMed ID: 2153375
[TBL] [Abstract][Full Text] [Related]
3. The relation between inhibition of cell growth and of dihydroorotic acid dehydrogenase by brequinar sodium.
de Kant E; Pinedo HM; Laurensse E; Peters GJ
Cancer Lett; 1989 Jul; 46(2):123-7. PubMed ID: 2546667
[TBL] [Abstract][Full Text] [Related]
4. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Peters GJ; Schwartsmann G; Nadal JC; Laurensse EJ; van Groeningen CJ; van der Vijgh WJ; Pinedo HM
Cancer Res; 1990 Aug; 50(15):4644-9. PubMed ID: 2164443
[TBL] [Abstract][Full Text] [Related]
5. Brequinar sodium: inhibition of dihydroorotic acid dehydrogenase, depletion of pyrimidine pools, and consequent inhibition of immune functions in vitro.
Simon P; Townsend RM; Harris RR; Jones EA; Jaffee BD
Transplant Proc; 1993 Jun; 25(3 Suppl 2):77-80. PubMed ID: 8390742
[No Abstract] [Full Text] [Related]
6. DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects.
Schwartsmann G; Peters GJ; Laurensse E; de Waal FC; Loonen AH; Leyva A; Pinedo HM
Biochem Pharmacol; 1988 Sep; 37(17):3257-66. PubMed ID: 2840910
[TBL] [Abstract][Full Text] [Related]
7. Differential susceptibility of dihydroorotate dehydrogenase/oxidase to Brequinar Sodium (NSC 368 390) in vitro.
Lakaschus G; Löffler M
Biochem Pharmacol; 1992 Mar; 43(5):1025-30. PubMed ID: 1313236
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
Chen SF; Perrella FW; Behrens DL; Papp LM
Cancer Res; 1992 Jul; 52(13):3521-7. PubMed ID: 1617622
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis.
Chen SF; Ruben RL; Dexter DL
Cancer Res; 1986 Oct; 46(10):5014-9. PubMed ID: 3019518
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase.
Chen SF; Papp LM; Ardecky RJ; Rao GV; Hesson DP; Forbes M; Dexter DL
Biochem Pharmacol; 1990 Aug; 40(4):709-14. PubMed ID: 2386542
[TBL] [Abstract][Full Text] [Related]
11. Cellular pharmacology of DUP-785, a new anticancer agent.
Anderson LW; Strong JM; Cysyk RL
Cancer Commun; 1989; 1(6):381-7. PubMed ID: 2562006
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.
Cleaveland ES; Zaharevitz DW; Kelley JA; Paull K; Cooney DA; Ford H
Biochem Biophys Res Commun; 1996 Jun; 223(3):654-9. PubMed ID: 8687451
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390).
Peters GJ; Sharma SL; Laurensse E; Pinedo HM
Invest New Drugs; 1987; 5(3):235-44. PubMed ID: 2822596
[TBL] [Abstract][Full Text] [Related]
14. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(12):666-678. PubMed ID: 30663496
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine.
Peters GJ; Kraal I; Pinedo HM
Br J Cancer; 1992 Feb; 65(2):229-33. PubMed ID: 1739622
[TBL] [Abstract][Full Text] [Related]
16. Effects of brequinar and ciprofloxacin on de novo nucleotide biosynthesis in mouse L1210 leukemia.
Lyons SD; Christopherson RI
Biochem Int; 1990 Dec; 22(6):939-49. PubMed ID: 1965281
[TBL] [Abstract][Full Text] [Related]
17. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(6):329-339. PubMed ID: 29723133
[TBL] [Abstract][Full Text] [Related]
18. Dihydroorotic acid dehydrogenase activity in actinomycin-D-treated and normal chick embryos.
Katdare SM; Katdare M; Joshi PN; Mulherkar L
Exp Cell Biol; 1988; 56(6):285-8. PubMed ID: 2852127
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts.
Braakhuis BJ; van Dongen GA; Peters GJ; van Walsum M; Snow GB
Cancer Lett; 1990 Feb; 49(2):133-7. PubMed ID: 2306706
[TBL] [Abstract][Full Text] [Related]
20. The "anti-pyrimidine effect" of hypoxia and brequinar sodium (NSC 368390) is of consequence for tumor cell growth.
Löffler M
Biochem Pharmacol; 1992 May; 43(10):2281-7. PubMed ID: 1599514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]